Literature DB >> 30504295

Treatment approach for the older, unfit patient with myeloma from diagnosis to relapse: perspectives of a European hematologist.

Thierry Facon1, Kenneth Anderson2.   

Abstract

Mrs. A. is a 73-year-old woman who has developed increasing fatigue and lower back pain over the past year. The pain limits her exercise tolerance such that she can now walk only 1 block. She is a retired schoolteacher who does volunteer efforts in her community but has limited her activities due to fatigue. Karnofsky performance status is 70%. She has a history of chronic hypertension treated with a diuretic, adult-onset diabetes mellitus treated with metformin, and hypothyroidism treated with levothyroxine. Initial evaluation reveals anemia, renal dysfunction, an elevated total protein, and an L2 compression fracture on lumbosacral radiographs. Results of initial and subsequent evaluation are shown below, and she is referred to a hematologist for further evaluation, which revealed the following: calcium 9.0 mg/dL, creatinine 3.2 mg/dL with estimated creatinine clearance using the Modification of Diet in Renal Disease equation of 15 mL/min, hemoglobin 9.6 g/dL, total protein 11 g/dL, albumin 3.2 g/dL, immunoglobulin A (IgA) λ M protein 6.8 g/dL, total IgA 7.2 g/dL, IgG 0.4 g/dL, IgM 0.03 g/dL, free κ <0.01 mg/L, free λ 1000 mg/L, free light chain ratio <0.01, β-2-microglobulin 4.2, viscosity 3.0, lactate dehydrogenase 200 U/L, urine protein electrophoresis: 125 mg/dL with 30% M protein, and urine immuno-electrophoresis: λ light chain. Skeletal bone survey showed lytic lesions in femurs and humeri and diffusely in ribs bilaterally as well as compression fractures at T4, T6, and L2. Bone marrow biopsy revealed λ-restricted plasma cells comprising 50% of the bone marrow core. Fluorescence in situ hybridization testing on marrow showed that del(17p) was present in 80% of the plasma cells. Mrs. A. is informed of the diagnosis of multiple myeloma and the need for therapy. She requests consultation with 2 of the leading world experts. However, she wants to be treated near her home and does not want treatment on a clinical trial.
© 2018 by The American Society of Hematology. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30504295      PMCID: PMC6245965          DOI: 10.1182/asheducation-2018.1.83

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN: 1520-4383


  29 in total

1.  Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  P Moreau; J San Miguel; P Sonneveld; M V Mateos; E Zamagni; H Avet-Loiseau; R Hajek; M A Dimopoulos; H Ludwig; H Einsele; S Zweegman; T Facon; M Cavo; E Terpos; H Goldschmidt; M Attal; C Buske
Journal:  Ann Oncol       Date:  2017-07-01       Impact factor: 32.976

2.  Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report.

Authors:  Antonio Palumbo; Sara Bringhen; Maria-Victoria Mateos; Alessandra Larocca; Thierry Facon; Shaji K Kumar; Massimo Offidani; Philip McCarthy; Andrea Evangelista; Sagar Lonial; Sonja Zweegman; Pellegrino Musto; Evangelos Terpos; Andrew Belch; Roman Hajek; Heinz Ludwig; A Keith Stewart; Philippe Moreau; Kenneth Anderson; Hermann Einsele; Brian G M Durie; Meletios A Dimopoulos; Ola Landgren; Jesus F San Miguel; Paul Richardson; Pieter Sonneveld; S Vincent Rajkumar
Journal:  Blood       Date:  2015-01-27       Impact factor: 22.113

3.  Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial.

Authors:  Cyrille Hulin; Andrew Belch; Chaim Shustik; Maria Teresa Petrucci; Ulrich Dührsen; Jin Lu; Kevin Song; Philippe Rodon; Brigitte Pégourié; Laurent Garderet; Hannah Hunter; Isabelle Azais; Richard Eek; Heinz Gisslinger; Margaret Macro; Shaker Dakhil; Cristina Goncalves; Richard LeBlanc; Ken Romeril; Bruno Royer; Chantal Doyen; Xavier Leleu; Fritz Offner; Nicolas Leupin; Vanessa Houck; Guang Chen; Annette Ervin-Haynes; Meletios A Dimopoulos; Thierry Facon
Journal:  J Clin Oncol       Date:  2016-10-20       Impact factor: 44.544

4.  Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores.

Authors:  Monika Engelhardt; Sandra Maria Dold; Gabriele Ihorst; Alexander Zober; Mandy Möller; Heike Reinhardt; Stefanie Hieke; Martin Schumacher; Ralph Wäsch
Journal:  Haematologica       Date:  2016-06-16       Impact factor: 9.941

5.  Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials.

Authors:  Sara Bringhen; Maria Victoria Mateos; Sonja Zweegman; Alessandra Larocca; Antonietta Pia Falcone; Albert Oriol; Davide Rossi; Maide Cavalli; Pierre Wijermans; Roberto Ria; Massimo Offidani; Juan Jose Lahuerta; Anna Marina Liberati; Roberto Mina; Vincenzo Callea; Martijn Schaafsma; Chiara Cerrato; Roberto Marasca; Luca Franceschini; Andrea Evangelista; Ana-Isabel Teruel; Bronno van der Holt; Vittorio Montefusco; Giovannino Ciccone; Mario Boccadoro; Jesus San Miguel; Pieter Sonneveld; Antonio Palumbo
Journal:  Haematologica       Date:  2013-02-26       Impact factor: 9.941

Review 6.  Autologous haematopoietic cell transplantation in elderly patients with multiple myeloma.

Authors:  Holger W Auner; Laurent Garderet; Nicolaus Kröger
Journal:  Br J Haematol       Date:  2015-07-27       Impact factor: 6.998

7.  Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.

Authors:  Antonio Palumbo; Hervé Avet-Loiseau; Stefania Oliva; Henk M Lokhorst; Hartmut Goldschmidt; Laura Rosinol; Paul Richardson; Simona Caltagirone; Juan José Lahuerta; Thierry Facon; Sara Bringhen; Francesca Gay; Michel Attal; Roberto Passera; Andrew Spencer; Massimo Offidani; Shaji Kumar; Pellegrino Musto; Sagar Lonial; Maria T Petrucci; Robert Z Orlowski; Elena Zamagni; Gareth Morgan; Meletios A Dimopoulos; Brian G M Durie; Kenneth C Anderson; Pieter Sonneveld; Jésus San Miguel; Michele Cavo; S Vincent Rajkumar; Philippe Moreau
Journal:  J Clin Oncol       Date:  2015-08-03       Impact factor: 44.544

8.  Autologous stem cell transplant for multiple myeloma patients 70 years or older.

Authors:  E Muchtar; D Dingli; S Kumar; F K Buadi; A Dispenzieri; S R Hayman; R C Wolf; D A Gastineau; R Chakraborty; W J Hogan; N Leung; P Kapoor; M Q Lacy; S V Rajkumar; M A Gertz
Journal:  Bone Marrow Transplant       Date:  2016-07-04       Impact factor: 5.483

9.  Multiple myeloma: patient outcomes in real-world practice.

Authors:  Kwee Yong; Michel Delforge; Christoph Driessen; Leah Fink; Alain Flinois; Sebastian Gonzalez-McQuire; Reza Safaei; Lionel Karlin; Maria-Victoria Mateos; Marc S Raab; Paul Schoen; Michele Cavo
Journal:  Br J Haematol       Date:  2016-07-13       Impact factor: 6.998

10.  A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients.

Authors:  Monika Engelhardt; Anne-Saskia Domm; Sandra Maria Dold; Gabriele Ihorst; Heike Reinhardt; Alexander Zober; Stefanie Hieke; Corine Baayen; Stefan Jürgen Müller; Hermann Einsele; Pieter Sonneveld; Ola Landgren; Martin Schumacher; Ralph Wäsch
Journal:  Haematologica       Date:  2017-02-02       Impact factor: 9.941

View more
  3 in total

1.  Carfilzomib combination treatment as first-line therapy in multiple myeloma: where do we go from the Carthadex (KTd)-trial update?

Authors:  Monika Engelhardt; Kwee Yong; Sara Bringhen; Ralph Wäsch
Journal:  Haematologica       Date:  2019-11       Impact factor: 9.941

2.  Defining the vulnerable patient with myeloma-a frailty position paper of the European Myeloma Network.

Authors:  Gordon Cook; Alessandra Larocca; Thierry Facon; Sonja Zweegman; Monika Engelhardt
Journal:  Leukemia       Date:  2020-06-18       Impact factor: 11.528

3.  Front-line treatment of multiple myeloma.

Authors:  Michele Cavo; Paola Tacchetti; Elena Zamagni
Journal:  Hemasphere       Date:  2019-06-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.